These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 34934428)

  • 1. Bullous pemphigoid: An immune disorder related to aging (Review).
    Deotto ML; Spiller A; Sernicola A; Alaibac M
    Exp Ther Med; 2022 Jan; 23(1):50. PubMed ID: 34934428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bullous Pemphigoid: Trigger and Predisposing Factors.
    Moro F; Fania L; Sinagra JLM; Salemme A; Di Zenzo G
    Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33050407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies.
    Lo Schiavo A; Ruocco E; Brancaccio G; Caccavale S; Ruocco V; Wolf R
    Clin Dermatol; 2013; 31(4):391-399. PubMed ID: 23806156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.
    Amber KT; Murrell DF; Schmidt E; Joly P; Borradori L
    Clin Rev Allergy Immunol; 2018 Feb; 54(1):26-51. PubMed ID: 28779299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The desmosome and hemidesmosome in cutaneous autoimmunity.
    Lin MS; Mascaró JM; Liu Z; España A; Diaz LA
    Clin Exp Immunol; 1997 Jan; 107 Suppl 1():9-15. PubMed ID: 9020929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers related to bullous pemphigoid activity and outcome.
    Giusti D; Le Jan S; Gatouillat G; Bernard P; Pham BN; Antonicelli F
    Exp Dermatol; 2017 Dec; 26(12):1240-1247. PubMed ID: 29105148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Autoimmune Skin Disease Bullous Pemphigoid: The Role of Mast Cells in Autoantibody-Induced Tissue Injury.
    Fang H; Zhang Y; Li N; Wang G; Liu Z
    Front Immunol; 2018; 9():407. PubMed ID: 29545809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances on the 180-kDa epidermal antigen in autoimmune subepidermal bullous skin diseases.
    Bernard P
    Springer Semin Immunopathol; 1992; 13(3-4):401-12. PubMed ID: 1411905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
    Atzori L; Deidda S; Aste N
    G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human skin basement membrane in health and in autoimmune diseases.
    Chan LS
    Front Biosci; 1997 Jul; 2():d343-52. PubMed ID: 9232815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Canine bullous pemphigoid (BP): identification of the 180-kd canine BP antigen by circulating autoantibodies.
    Iwasaki T; Olivry T; Lapiere JC; Chan LS; Peavey C; Liu YY; Jones JC; Ihrke PJ; Woodley DT
    Vet Pathol; 1995 Jul; 32(4):387-93. PubMed ID: 7483213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of physical factors in the pathogenesis of bullous pemphigoid: Case report series and a comprehensive review of the published work.
    Dănescu S; Chiorean R; Macovei V; Sitaru C; Baican A
    J Dermatol; 2016 Feb; 43(2):134-40. PubMed ID: 26173987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders.
    Didona D; Scarsella L; Fehresti M; Solimani F; Juratli HA; Göbel M; Mühlenbein S; Holiangu L; Pieper J; Korff V; Schmidt T; Sitaru C; Eming R; Hertl M; Pollmann R
    Front Immunol; 2021; 12():569287. PubMed ID: 33841390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A blistering new era for bullous pemphigoid: A scoping review of current therapies, ongoing clinical trials, and future directions.
    Khalid SN; Khan ZA; Ali MH; Almas T; Khedro T; Raj Nagarajan V
    Ann Med Surg (Lond); 2021 Oct; 70():102799. PubMed ID: 34540212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human autoantibodies against the 230-kD bullous pemphigoid antigen (BPAG1) bind only to the intracellular domain of the hemidesmosome, whereas those against the 180-kD bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the hemidesmosome in normal human and swine skin.
    Ishiko A; Shimizu H; Kikuchi A; Ebihara T; Hashimoto T; Nishikawa T
    J Clin Invest; 1993 Apr; 91(4):1608-15. PubMed ID: 7682575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment.
    Bernard P; Antonicelli F
    Am J Clin Dermatol; 2017 Aug; 18(4):513-528. PubMed ID: 28247089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bullous pemphigoid: clinical practice guidelines.
    Fuertes de Vega I; Iranzo-Fernández P; Mascaró-Galy JM
    Actas Dermosifiliogr; 2014 May; 105(4):328-46. PubMed ID: 23540594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid.
    Zhou T; Peng B; Geng S
    Front Immunol; 2021; 12():718073. PubMed ID: 34504496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eosinophils as putative therapeutic targets in bullous pemphigoid.
    Simon D; Borradori L; Simon HU
    Exp Dermatol; 2017 Dec; 26(12):1187-1192. PubMed ID: 28833620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model.
    Liu Z; Sui W; Zhao M; Li Z; Li N; Thresher R; Giudice GJ; Fairley JA; Sitaru C; Zillikens D; Ning G; Marinkovich MP; Diaz LA
    J Autoimmun; 2008 Dec; 31(4):331-8. PubMed ID: 18922680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.